Outcomes4Me is a 2024 Fast Company World Changing Idea! Learn more >>
Outcomes4Me is a 2024 Fast Company World Changing Idea! Learn more >>
Suzanne Garner
Cancer Survivor, Outcomes4Me User
We’re the only DCIS HER2- breast cancer app that integrates with the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), from the not-for-profit alliance of 33 leading cancer centers. The NCCN Guidelines® include comprehensive guidance related to all FDA-approved treatment options.
We gather DCIS HER2- breast cancer treatment recommendations typically meant for oncologists and use Artificial Intelligence (AI) to translate that information so you can understand it, putting you in control. With this knowledge, you can feel empowered to make the best medical decisions with your care team.
With our free DCIS HER2- breast cancer app, you’ll get:
Gain direct access to personalized treatment options so you can have more informed conversations with your care team.
Rely on us to help your patients get access to the best DCIS HER2- breast cancer care and resources, and save time in your day. We’re here to help and won’t ever get in the way.
Accelerate patient access to your treatments and expand the reach of your DCIS HER2- breast cancer research and clinical trials.
Get all the information you need to take a more active role in treating your DCIS HER2- breast cancer.
Yes, DCIS can be either Her2-negative or positive. However, at this time the prognostic significance of Her2 status in DCIS is not well established and as a result it is currently not recommended to test for Her2 status.
At this time the prognostic significance of Her2 status in DCIS is not well established and as a result it is currently not recommended to test for Her2 status. Therefore there is no data on DCIS survival based on her2 status.
[SOURCE NCCN ] Although the tumor HER2 status is of prognostic significance in invasive cancer, its importance in DCIS has not been established. To date, studies have either found unclear or weak evidence of HER2 status as a prognostic indicator in DCIS, 5-8 and no statistically significant benefit to the use of trastuzumab concurrently with radiation in HER2-amplified DCIS.9 The NCCN Panel has concluded that HER2 status for DCIS does not alter the management strategy and therefore is not recommended for DCIS. (Directly copied from NCCN guidelines discussion section – needs to be reworded)
By clicking the “Subscribe Now” button you’re agreeing to our Terms of Service and Privacy Policy.
